Navigation Links
DCIS patients who get invasive breast cancer have higher mortality
Date:3/11/2011

Women with ductal carcinoma in situDCISwho later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.

Retrospective studies of women with DCIS have compared breast conserving surgery (lumpectomy) to mastectomy and found that survival rates are similar. However, women who have lumpectomy alone, without further treatment, are at higher risk of developing invasive breast cancer in the same breast. Whether women who develop invasive breast tumors after DCIS are also at higher risk of dying of breast cancer has not been clear.

To explore this question as well as the long-term effects of treatments aimed at avoiding invasive recurrence after lumpectomy, Irene Wapnir, M.D., of Stanford University School of Medicine, and James Dignam, PhD of University of Chicago looked at the long-term outcomes of patients with localized DCIS who took part in two large randomized trials, both carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP). The B-17 trial compared lumpectomy alone to lumpectomy plus radiation therapy in women with DCIS. The B-24 trial compared lumpectomy plus radiation in combination with either tamoxifen or placebo.

Wapnir and colleagues analyzed data on outcomes in both trials after 15 years, including overall and breast cancer-specific survival and survival after development of invasive breast cancer in the same, or ipsilateral, breast.

They found that the development of invasive ipsilateral breast cancer was associated with death rates that were statistically significantly higher than those in women who did not develop an invasive ipsilateral breast cancer. Recurrence of DCIS was not associated with higher mortality. Radiation treatment after lumpectomy reduced the risk of ipsilateral invasive breast cancer compared to lumpectomy alone, and treatment with radiation and tamoxifen reduced the risk compared to radiation only. The reductions in risk were statistically significant.

Among all patients in the trials, the 15-year cumulative incidence of death from breast cancer was 4.7% or less for all treatment groups. Some of these events could be attributed to new invasive contralateral breast cancers.

The authors conclude that, regardless of treatment, women with DCIS have an excellent overall prognosis "despite persistent risks of breast cancer in the same or contralateral breast." They note that three other NSABP trials now in progress will provide more information on other treatment options following lumpectomy.


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. 70 percent of prostate cancer patients on ADT gain significant weight in first year
2. Research suggests HIV-infected patients at higher risk for bone fractures
3. Hopkins Childrens study finds some patients with cerebral palsy have asymmetric pelvic bones
4. Study: Homeless patients cost $2,500 more than the average patient for each hospital stay
5. Family Involvement Helps Stroke Patients With Rehab
6. University of Michigan Cardiovascular Center studies new treatment for high-risk aortic patients
7. Abnormal neural activity recorded from the deep brain of Parkinsons disease and dystonia patients
8. Hospitals Urged to Check for Depression Before Discharging Heart Patients
9. Epilepsy-linked memory losss worries more patients than doctors
10. Cancer in HIV-positive patients
11. HBV infection decreases risk of liver metastasis in colorectal cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow ... up with one of the top website design companies to create a state ... articles related to the law firm's main practice areas. These practice areas include: ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals ... cellular and metabolic health. This synergistic combination of omega-3 fatty acids and potent ... 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , ...
(Date:5/4/2016)... ... 04, 2016 , ... Natalie Jill is a well respected lifestyle ... of the launch of her new book: Natalie Jill’s 7 Day Jump Start: Unprocess ... to jump start a new healthy lifestyle featuring simple recipes using MitoXcell’s raw cacao ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco Products has announced the ... dual-light flashlights in models NSP-9842XL and NSR-9844XL . , First previewed at ... uses 2 included CR-123 batteries to produce up to 650 lumens in a ...
(Date:5/4/2016)... (PRWEB) , ... May 04, ... ... next-level compression and support for knees, ankles, and elbows. Engineered with athletes ... Innovative 3D flat-bed manufacturing (opposed to ineffective circular knitting, common in the ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Valeritas Holdings, Inc. (OTCQB: VLRX) ... offering (APO). This was accomplished via a reverse merger ... a private placement of approximately 5 million shares of ... Under the terms of the reverse merger, which ... will trade on the OTC Markets under the symbol ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
(Date:5/3/2016)... India , May 4, 2016 ... spreads across 154 pages, profiling 09 key companies ... is a professional and in-depth study on the ... a basic overview of the industry including definitions, ... Needles market analysis is provided for the international ...
Breaking Medicine Technology: